科塞特不动产

Cencora's 15min chart triggers MACD Death Cross, KDJ Death Cross.

Evercore ISI Downgrades Cencora PT to $420 from $440, Maintains Outperform Rating

Cencora

Connection Q4 CY2025 Revenue Falls Short of Estimates, Non-GAAP Profit Beats Consensus

Cencora Q1 2026 Earnings Call Highlights: US Growth Amid International Challenges

Cencora's 15min chart triggered Bollinger Bands Narrowing, KDJ Death Cross confirmed.

Catalyst<ul> <li>Most analysts rate COR Buy or Strong Buy, showing broad institutional optimism.</li> <li>Positive fundamental factors include strong cash reserves relative to market value and favorable profitability versus valuation metrics.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Fund flows indicate negative net inflow in small, medium, and extra-large orders, suggesting outflows by larger investors.</li> <li>Fundamental factors show unfavorable revenue relative to market value and a decline in net cash flow from operating activities compared to the previous year.</li></ul>

Key Factors

Cencora (COR) reported Q1 2026 revenue of $85.9 billion, up 5.5% year-over-year, and adjusted EPS of $4.08, beating estimates by $0.04. The company raised its fiscal 2026 guidance for operating income growth to 11.5%-13.5%, driven by the OneOncology acquisition and strong U.S. Healthcare Solutions performance. Cencora declared a $0.60 quarterly dividend, payable March 2, maintaining a forward yield of 0.66%.

COR News